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The increase in multidrug-resistant tuberculosis (MDR-TB), 
defined as Mycobacterium tuberculosis resistant in vitro to at least 
isoniazid (INH) and rifampicin (RIF), is a global concern. It is 
estimated that 511 000 MDR-TB cases occur globally each year. 
The World Health Organization (WHO) consequently released 
an emergency update on their management guidelines, 
recommending that treatment of MDR-TB should include 
at least 4 effective drugs, and that standardised treatment 
regimens should be based on resistance patterns for each 
country/region. Most importantly, treatment regimens should 
not depend on the results of drug susceptibility testing (DST) 
for ethambutol (EMB) or pyrazinamide (PZA). In response, 
the South African Department of Health prepared a draft 
drug-resistant TB treatment policy in which PZA remains 
one of the 4 effective drugs, while EMB should be replaced 
with terizidone or cycloserine, if there is resistance to EMB 
(disregarding inaccurate DST). In South Africa, there is a 
high frequency of undetected EMB and PZA resistance and 
their association with MDR-TB. Therefore, we recommend 
that the WHO guidelines in which 4 other effective drugs are 
used to treat MDR-TB, be followed more closely. EMB and 
PZA can be included if they are not counted as one of the 4 
effective drugs. However, this does not address the root cause 
of the amplification of resistance in undiagnosed MDR-TB 
patients in South Africa, which can only be achieved by the 
implementation of rapid DST methods in all TB cases before 
initiating therapy. This protocol would curb the amplification 
of resistance and the evolution of XDR-TB.
The number of MDR-TB cases has steadily increased despite 
the widespread implementation of the directly observed 
treatment short-course (DOTS) and DOTS-plus strategies.1,2 
A survey in South Africa estimates that 1.8% of new TB cases 
and 6.7% of retreatment TB cases are MDR-TB,1 equating to 
approximately 14 000 MDR-TB cases each year.1 The manner 
in which the WHO DOTS strategy has been implemented in 
South Africa to control TB might have inadvertently lead to the 
amplification of resistance in MDR-TB cases.3-5 Consequently, it 
is important to review the epidemiology of drug resistance in 
the country and make informed evidence-based suggestions on 
improving the current treatment strategy.
The WHO DOTS-plus treatment guidelines for treating 
MDR-TB focus on the use of various bactericidal or 
bacteriostatic antituberculosis drugs with a proven efficacy 
against M. tuberculosis. They are classed as either first-line 
(normally used to treat new and drug-susceptible TB cases) 
or second-line (normally used to treat MDR-TB or extensively 
drug-resistant TB (XDR-TB)). EMB and PZA, two first-line 
drugs, are often used in combination with various second-
line drugs to treat MDR/XDR-TB. Their inclusion in the latter 
treatment regimen was based on the absence of alternative 
second-line drugs and surveillance data (or lack thereof), 
which suggests that resistance to EMB and PZA is rare.6 
However, DST for both EMB and PZA is inaccurate.7,8 The 
National Health Laboratory Service (NHLS) in Cape Town 
missed 90% of EMB resistance using the indirect proportion 
method on Middlebrook solid medium compared with a liquid 
culture medium.7 Of the EMB-resistant isolates, 87% were 
also resistant to INH and RIF. These results were confirmed 
by DNA sequencing which identified mutations in the embB 
gene which conferred resistance to EMB in all the above 
isolates.7,9 In 2008, we showed in a cohort of 228 MDR-TB 
isolates from the Western Cape that 131 (57.5%) harboured 
mutations in the embB gene, suggesting that they were resistant 
to EMB (unpublished data). Only 9.4% were phenotypically 
resistant by routine culture on solid media. In a drug resistance 
surveillance study in children in the Western Cape from March 
2007 through February 2009, 12 out of 24 (50%) with confirmed 
MDR-TB were phenotypically resistant to EMB, confirming 
the high rate of EMB resistance in adult MDR-TB cases (HSS, 
personal communication).
DST for PZA is not routinely performed in South Africa 
owing to the complexity of the culture conditions (low pH 
medium is required, which negatively affects the growth and 
viability of M. tuberculosis).10 To address the largely unknown 
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frequency of resistance to PZA, a recent study (using the non-
radiometric BACTEC mycobacteria growth indicator tube 
(MGIT) 960 method) showed that 53.5% of drug-resistant 
isolates (various resistance patterns) from the Western Cape 
were resistant to PZA. This finding was confirmed by DNA 
sequencing of the pncA gene, which encodes for the mechanism 
of resistance.8,11 This study importantly showed a highly 
significant association between MDR-TB and PZA resistance 
(p<0.001)8 that was confirmed in isolates collected as part of 
a national drug-resistance survey where 52.1% of MDR-TB 
isolates showed additional resistance to PZA.6
The association between EMB and PZA resistance and 
MDR-TB in South Africa (a setting where MDR-TB is primarily 
transmitted12) stems from the manner in which the DOTS 
strategy has been implemented since implementation in 1996. 
New TB cases are routinely diagnosed by sputum smear 
microscopy or culture without DST. In the absence of routine 
DST, it is assumed that all new TB cases are drug-susceptible 
until treatment failure or relapse occurs. Therefore, according 
to the current 2004 South African treatment guidelines (South 
African National Tuberculosis Control Programme Practical 
Guidelines 2004), a new TB patient with undiagnosed MDR-
TB will be treated with 4 first-line drugs (INH, RIF, PZA 
and EMB) during the intensive phase of therapy (the first 
2 months), which implies that the treatment regimen will 
contain only 2 effective drugs: EMB and PZA. Since PZA is a 
poor companion drug to prevent the acquisition of resistance, 
it is highly probable that resistance to EMB and/or PZA 
will follow, as is evident by the above data. If patients fail to 
show sputum conversion after 5 months of treatment, they 
would be regarded as a treatment failure and be shifted to 
the category II regimen (i.e. South African current retreatment 
guidelines) with the addition of streptomycin (SM) in the 
first 2 months of retreatment. DST will then be requested 
(which may take months14), during which time resistance to 
any remaining effective drugs may develop (i.e. EMB, PZA 
and/or SM). Consequently, the MDR-TB epidemic will become 
largely associated with EMB, PZA and SM resistance. In 
addition, during the diagnostic delay period, transmission to 
close contacts may occur, thereby perpetuating the MDR-TB 
epidemic.
According to the South African National Tuberculosis 
Control Programme Practical Guidelines 2004, a patient will 
only be placed on the standardised treatment for MDR-TB 
after DST results become available. This could be at least 6 - 7 
months after initial therapy started. The patient will be placed 
on the current standardised MDR-TB treatment regimen which 
includes a fluoroquinolone (usually ofloxacin or ciprofloxacin), 
amikacin (AM) or kanamycin (KM), ethionamide (for which 
the strain may be resistant if inhA promoter region mutation 
is the cause of INH resistance), PZA and EMB (replaced with 
cycloserine or terizidone if resistant to EMB). Resistance to 
PZA,8 EMB7 and ethionamide13 is commonly associated with 
MDR-TB and, if not detected, patients with MDR-TB may 
only receive 2 effective drugs (a fluoroquinolone and AM or 
KM) of which AM or KM is not used during the 12 - 18-month 
continuation phase of therapy. This situation could lead to 
unintentional monotherapy during the continuation phase, 
with possible acquisition of resistance to the fluoroquinolones, 
leading to pre-XDR-TB (one resistance mutation away from 
XDR-TB).12 Therefore, many MDR/XDR-TB cases are presently 
being inadvertently under-treated, which may strongly 
influence treatment outcome. This scenario may be repeated 
as treatment regimens are adjusted, leading to the eventual 
evolution of XDR-TB.4
To address the difficulties associated with DST for EMB 
and PZA, the WHO in 2008 released an emergency update 
on guidelines for treating drug-resistant TB in which they 
acknowledged that MDR-TB treatment regimens should not 
be dependent on the results of DST for EMB or PZA.15 They 
recommended that treatment of MDR/XDR-TB should include 
at least 4 drugs with certain or almost certain effectiveness. 
Treatment regimens can be individualised or standardised if 
resistance patterns for the country/region are known. EMB 
could be included in a regimen provided that it is not counted 
as one of the effective 4 drugs, and that PZA may be used 
for the entire treatment if deemed effective (based on DST) 
but must also not be counted as one of the 4 effective drugs. 
Ciprofloxacin is no longer recommended for treatment of TB.15
New draft policy guidelines (2008) are being formulated by 
the South African National TB Control Programme based on 
the WHO recommendations. These guidelines aim to address 
diagnostic delay as well as treatment of MDR/XDR-TB. 
They suggest that DST should be done on patients failing to 
show clinical or bacteriological improvement at 2 months of 
treatment or at 3 months in cases where the intensive phase 
was extended (as opposed to 5 months in the old guidelines). 
In contrast to the WHO, these guidelines recommend that DST 
for EMB determines the treatment regimen for MDR/XDR-
TB. If susceptible, EMB should be included in the regimen 
as the 5th drug (this disregards the inaccuracy of EMB DST). 
If resistant, EMB should be replaced with terizidone or 
cycloserine as the 5th drug. These guidelines also recommend 
the inclusion of PZA as one of the 4 effective drugs but 
acknowledge that, in the absence of DST, it should be assumed 
that all isolates are resistant. Given the strong evidence of high 
levels of resistance to PZA in South Africa associated with 
MDR-TB, we suggest that, in the absence of DST for PZA, this 
drug should not be counted as one of the 4 effective drugs, 
but may be included in the regimen. In light of the WHO 
recommendations and the high levels of undetected resistance 
to EMB and PZA in South Africa, it is essential that the revised 
guidelines for MDR-TB treatment are implemented in South 
Africa together with improved routine DST. In the interim, it 
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should be assumed that all MDR-TB cases are resistant to EMB 
and PZA and, although treatment with these drugs can be 
continued, they should not be counted as one of the 4 effective 
drugs, to prevent the emergence of additional resistance and 
the possible evolution of XDR-TB.
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